Natixis Advisors LLC Cuts Holdings in Progyny, Inc. (NASDAQ:PGNY)

Natixis Advisors LLC reduced its holdings in Progyny, Inc. (NASDAQ:PGNY) by 20.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,581 shares of the company’s stock after selling 5,802 shares during the quarter. Natixis Advisors LLC’s holdings in Progyny were worth $390,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC lifted its stake in shares of Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Progyny in the fourth quarter valued at about $74,000. Finally, KBC Group NV boosted its holdings in Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock worth $81,000 after buying an additional 2,140 shares in the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PGNY has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group lifted their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. Finally, Bank of America boosted their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $24.82.

Progyny Stock Performance

Shares of PGNY opened at $22.31 on Friday. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $38.98. The company’s 50 day simple moving average is $22.05 and its 200 day simple moving average is $18.58. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.47, a PEG ratio of 2.39 and a beta of 1.41.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.